Abstract
Development of a preventive immunogen for human immunodeficiency virus (HIV) infection is a national priority. The complexities associated with HIV host-virus interactions, coupled with the rapid progression of the HIV epidemic worldwide, have necessitated lowering expectations for an HIV vaccine that is 100 percent effective and have raised important scientific and nonscientific issues regarding development and use of preventive and therapeutic HIV vaccines.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
AIDS Vaccines* / immunology
-
AIDS Vaccines* / therapeutic use
-
Acquired Immunodeficiency Syndrome / prevention & control*
-
Acquired Immunodeficiency Syndrome / therapy*
-
Animals
-
Behavioral Research
-
Biomedical Research
-
Clinical Trials as Topic
-
Developing Countries
-
Ethics, Medical
-
Federal Government
-
HIV Antigens / immunology
-
HIV Infections / prevention & control*
-
HIV Infections / therapy*
-
HIV Seropositivity
-
Internationality
-
Nontherapeutic Human Experimentation
-
Research Subjects
-
Risk Assessment*
-
Social Responsibility
-
Therapeutic Human Experimentation
Substances
-
AIDS Vaccines
-
HIV Antigens